
Atopic Dermatitis Drugs
Description
Global Atopic Dermatitis Drugs Market to Reach US$38.4 Billion by 2030
The global market for Atopic Dermatitis Drugs estimated at US$12.2 Billion in the year 2024, is expected to reach US$38.4 Billion by 2030, growing at a CAGR of 21.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$18.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 21.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 27.0% CAGR
The Atopic Dermatitis Drugs market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2030 trailing a CAGR of 27.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.5% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.4% CAGR.
strong>Global Atopic Dermatitis Drugs Market - Key Trends and Drivers Summarized
Why Are Atopic Dermatitis Drugs Essential in Managing This Chronic Skin Condition?
Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that affects millions of individuals worldwide, particularly children. Characterized by itchy, red, and swollen skin, atopic dermatitis can significantly impact a patient`s quality of life, leading to discomfort, sleep disturbances, and even psychological stress. The management of atopic dermatitis typically involves a combination of topical therapies, systemic treatments, and lifestyle modifications aimed at reducing symptoms, preventing flare-ups, and maintaining skin barrier function. Topical corticosteroids and calcineurin inhibitors have long been the cornerstone of treatment, providing relief by reducing inflammation and controlling itching. However, as our understanding of the disease`s complex immunological mechanisms has evolved, so too have the therapeutic options available, with newer drugs targeting specific pathways involved in the inflammatory process. These advancements in atopic dermatitis drugs are crucial for providing more effective and targeted treatment options for patients suffering from moderate to severe forms of the disease.
How Are Technological Innovations Expanding Treatment Options for Atopic Dermatitis?
Technological innovations have significantly broadened the treatment landscape for atopic dermatitis, introducing new classes of drugs that offer more targeted and effective therapies. One of the most notable advancements has been the development of biologics, which are designed to target specific proteins involved in the inflammatory process, such as interleukin-4 (IL-4) and interleukin-13 (IL-13). These biologics, such as dupilumab, have shown remarkable efficacy in reducing the severity of symptoms in patients with moderate to severe atopic dermatitis who do not respond adequately to conventional therapies. Additionally, the emergence of Janus kinase (JAK) inhibitors represents another breakthrough, offering a new oral treatment option that can modulate immune signaling pathways implicated in atopic dermatitis. These drugs provide an alternative for patients who are either resistant to or cannot tolerate existing treatments. Furthermore, advancements in drug delivery systems, such as topical formulations that enhance skin penetration and reduce systemic absorption, are improving the safety and efficacy of atopic dermatitis therapies, making them more accessible and convenient for patients.
What Market Trends Are Driving the Adoption of New Atopic Dermatitis Drugs?
Several key market trends are driving the adoption of new atopic dermatitis drugs, reflecting the growing demand for more effective and personalized treatment options. The increasing prevalence of atopic dermatitis, particularly in urban areas where environmental factors such as pollution and allergens are more prevalent, has heightened the need for advanced therapies. Additionally, the rising awareness of atopic dermatitis and its impact on quality of life is prompting more patients to seek medical treatment, leading to higher demand for effective drugs. The trend towards personalized medicine is also influencing the market, with healthcare providers increasingly tailoring treatment plans to individual patients based on their disease severity, comorbidities, and response to prior therapies. Moreover, the expanding use of telemedicine and digital health platforms is improving access to dermatological care, enabling more timely diagnosis and treatment of atopic dermatitis. These trends are contributing to the rapid growth of the atopic dermatitis drug market, as patients and healthcare providers seek out the latest and most effective treatment options.
What Factors Are Driving the Growth of the Atopic Dermatitis Drug Market?
The growth in the atopic dermatitis drug market is driven by several factors that are reshaping the landscape of dermatological treatment. A primary driver is the increasing prevalence of atopic dermatitis globally, which is leading to greater demand for effective treatment options. Technological advancements in drug development, particularly the introduction of biologics and JAK inhibitors, are also fueling market growth by providing new and more effective therapies for patients with moderate to severe disease. The expansion of healthcare infrastructure in emerging markets, along with increasing investments in dermatological research, is further boosting the availability and adoption of these advanced therapies. Additionally, the growing focus on patient-centered care and the trend towards personalized medicine are driving the development and use of drugs that are tailored to the specific needs of individual patients. As these factors continue to influence the market, the atopic dermatitis drug industry is expected to experience sustained growth, driven by innovation, rising patient awareness, and the increasing demand for targeted and effective treatments.
SCOPE OF STUDY:The report analyzes the Atopic Dermatitis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors, Other Drug Classes); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 12 Featured) -
- Allergan Plc
- Anacor Pharmaceutical Inc.
- Astellas Pharma, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Encore Dermatology
- Leo Pharma
- Meda Pharmaceuticals
- Mylan
- Novartis International AG
- Pfizer
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Valent Pharmaceutical Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Atopic Dermatitis Drugs – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- Global Economic Update
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Atopic Dermatitis Propels Growth in Therapeutics Market
- Increasing Demand for Personalized Medicine Expands Addressable Market Opportunity
- Innovation in Drug Delivery Systems Drives Adoption of Topical and Oral Therapies
- Growing Awareness of Atopic Dermatitis Among Patients Spurs Market Growth
- Impact of Environmental Factors on Atopic Dermatitis Incidence Accelerates Demand for Advanced Treatments
- Emergence of Personalized Treatment Plans Expands Opportunities for Tailored Therapies
- Increasing Use of Biologics in Pediatric Patients Drives Adoption of New Therapies
- Shift Towards Non-Steroidal Treatments Generates New Market Opportunities
- Innovations in Immunomodulatory Drugs Strengthen Case for Targeted Atopic Dermatitis Therapies
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for Atopic Dermatitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 8: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 9: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 12: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 13: World Atopic Dermatitis Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Skin Barrier Emollients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Skin Barrier Emollients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Skin Barrier Emollients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for PDE4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for PDE4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for PDE4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: USA 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Canada 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- JAPAN
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Japan 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- CHINA
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: China 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: China Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: China 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- EUROPE
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Atopic Dermatitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- FRANCE
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: France 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: France Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: France 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- GERMANY
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Germany 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Italy 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: UK 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: UK 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 86: Spain Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Spain 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 89: Spain Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Spain Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Spain 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 92: Russia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Russia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 95: Russia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Russia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Russia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Rest of Europe 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Rest of Europe Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Rest of Europe 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- AUSTRALIA
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 113: Australia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Australia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 116: Australia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Australia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Australia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- INDIA
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 119: India Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: India Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: India 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 122: India Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: India Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: India 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: South Korea 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 128: South Korea Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: South Korea Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: South Korea 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Atopic Dermatitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 143: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Latin America Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Argentina 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 149: Argentina Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Argentina Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Argentina 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Brazil 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 155: Brazil Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Brazil Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Brazil 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Mexico 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 161: Mexico Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Mexico Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Mexico 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Rest of Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Rest of Latin America Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Rest of Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Atopic Dermatitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 176: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Middle East Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- IRAN
- TABLE 179: Iran Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: Iran 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 182: Iran Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Iran Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: Iran 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 185: Israel Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: Israel 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 188: Israel Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: Israel Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: Israel 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Saudi Arabia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Saudi Arabia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Saudi Arabia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 197: UAE Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: UAE 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 200: UAE Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: UAE Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: UAE 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Rest of Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Rest of Middle East Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Rest of Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- AFRICA
- Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 209: Africa Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Africa 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 212: Africa Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Africa Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Africa 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates